Chunyi Hao

5.6k total citations · 2 hit papers
135 papers, 2.1k citations indexed

About

Chunyi Hao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Chunyi Hao has authored 135 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 33 papers in Surgery. Recurrent topics in Chunyi Hao's work include Pancreatic and Hepatic Oncology Research (36 papers), Sarcoma Diagnosis and Treatment (36 papers) and Hepatocellular Carcinoma Treatment and Prognosis (19 papers). Chunyi Hao is often cited by papers focused on Pancreatic and Hepatic Oncology Research (36 papers), Sarcoma Diagnosis and Treatment (36 papers) and Hepatocellular Carcinoma Treatment and Prognosis (19 papers). Chunyi Hao collaborates with scholars based in China, Ethiopia and United States. Chunyi Hao's co-authors include Xiuyun Tian, Xiaoya Guan, Jianhui Wu, Ang Lv, Min Zhao, Hong-Gang Qian, Yan Liang, Bin Dong, Jiafu Ji and Hui Qiu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Analytical Chemistry.

In The Last Decade

Chunyi Hao

125 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

2022 101 citations Xu Zhu, Guang Cao et al. Radiology profile →

Peers

Countries citing papers authored by Chunyi Hao

Since Specialization

Citations

This map shows the geographic impact of Chunyi Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunyi Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunyi Hao more than expected).

Fields of papers citing papers by Chunyi Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunyi Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunyi Hao. The network helps show where Chunyi Hao may publish in the future.

Co-authorship network of co-authors of Chunyi Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Chunyi Hao. A scholar is included among the top collaborators of Chunyi Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunyi Hao. Chunyi Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress 2024 ·Cell Death Discovery ·(unknown), (unknown), Hao Yu, Yifan Wu, Yan Liang, Xiaoya Guan, Bin Dong, Min Zhao, Xiuyun Tian, Chunyi Hao, Jianhui Wu	1
2	Surgical outcomes of major vascular resection for retroperitoneal liposarcoma from a high‑volume sarcoma center: a propensity score matching analysis 2024 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Bonan Liu, Chengpeng Li, Ang Lv, Xiuyun Tian, Jianhui Wu, Hui Qiu, Chunyi Hao	0
3	Implication of Capillary Morphogenesis Gene 2 (CMG2) in the Disease Progression and Peritoneal Metastasis of Pancreatic Cancer 2024 ·Cancers ·(unknown), (unknown), (unknown), Fiona Ruge, (unknown), (unknown), (unknown), Paul Griffiths, Kate Murphy, Matthew Pugh, Chunyi Hao, Wen G. Jiang, Lin Ye	0
4	Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial 2024 ·Clinical Cancer Research ·Yajin Chen, Chengyou Du, Shunli Shen, (unknown), Yunfeng Shan, (unknown), Jianhui Wu, Changzhen Shang, (unknown), (unknown), Heng Xiao, Jianguo Qiu, Yunpeng Hua, Shutong Wang, (unknown), Shengjie Dai, (unknown), (unknown), (unknown), Chunyi Hao	7
5	Rapid and Precise Diagnosis of Retroperitoneal Liposarcoma with Deep-Learned Label-Free Molecular Microscopy 2024 ·Analytical Chemistry ·(unknown), (unknown), (unknown), X. G. Chen, (unknown), Xiuyun Tian, Chunyi Hao, Shuhua Yue	0
6	Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients 2024 ·Cancer Medicine ·(unknown), Weiwei Fu, Wei Xu, (unknown), Xiuyun Tian, Chunyi Hao, Shigang Ding	2
7	Surgical outcomes of locally advanced gastrointestinal stromal tumors after multivisceral resection: A retrospective study of 64 patients at a single institution 2023 ·Intractable & Rare Diseases Research ·Hui Qiu, Zhen Wang, Bonan Liu, (unknown), Xiuyun Tian, Chunyi Hao	0
8	Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study 2023 ·Annals of Translational Medicine ·(unknown), Chengpeng Li, Bonan Liu, Qiao Liu, (unknown), Zhen Wang, Xiaopeng Wang, Weiwei Jia, Xiuyun Tian, Chunyi Hao	5
9	A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. 2023 ·Journal of Clinical Oncology ·Jianming Xu, Jianping Xiong, Shanzhi Gu, Zuoxing Niu, Fei Yin, Beicheng Sun, Lan Zhang, Fuxiang Zhou, Chunyi Hao, (unknown), Wensheng Qiu, Yi Gao, Yongxin Ren, Songhua Fan, Michael Shi, Weiguo Su	1
10	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial breakdown → 2022 ·Journal of Clinical Oncology ·Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaohong Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao	127
11	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial breakdown → 2022 ·Radiology ·(unknown), Xu Zhu, (unknown), Guang Cao, Wenqing Li, Liang Xu, Hui Chen, Di Wu, Renjie Yang, Kun Wang, Wei Liu, Hongwei Wang, Quan Bao, Ming Liu, Chunyi Hao, Lin Shen, Baocai Xing, Xiaodong Wang	101
12	Development and validation of a nomogram for predicting the prognosis in cancer patients with sepsis 2022 ·Cancer Medicine ·Yong Yang, Jun Dong, Li Yang, (unknown), Xiuyun Tian, Hongzhi Wang, Chunyi Hao	9
13	Biomineralization Synthesis of the Cobalt Nanozyme in SP94-Ferritin Nanocages for Prognostic Diagnosis of Hepatocellular Carcinoma 2019 ·ACS Applied Materials & Interfaces ·Bing Jiang, Yan Liang, Jianlin Zhang, Meng Zhou, Guizhi Shi, Xiuyun Tian, Kelong Fan, Chunyi Hao, Xiyun Yan	96
14	A novel scoring system to predict ascites development post hepatectomy for BCLC stage B hepatocellular carcinoma 2018 ·Translational Cancer Research ·Hong-Gang Qian, Liying Wu, Chengpeng Li, Ang Lv, Jianhui Wu, Bonan Liu, Xiuyun Tian, Wei Xu, Chunyi Hao	2
15	Use of 18F-FDG-PET/CT for Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas 2018 ·Contrast Media & Molecular Imaging ·(unknown), Zhongwu Li, (unknown), Min Zhao, (unknown), Chunyi Hao	14
16	Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases 2018 ·Journal of Cancer Research and Therapeutics ·Yong Li, Guoxin Li, Zhonghua Chu, Chunyi Hao, Zhiwei Jiang, Huanqiu Chen, (unknown), Dechuan Li, Bing Hu, Xishan Wang, (unknown)	3
17	<i>En bloc</i> resection for intra-abdominal/retroperitoneal desmoid-type fibromatosis with adjacent organ involvement: A case series and literature review 2018 ·BioScience Trends ·Zhen Wang, Jianhui Wu, Ang Lv, Xiuyun Tian, Chunyi Hao	6
18	IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy. 2016 ·PubMed ·Yongning Jia, Ke Ji, Jiafu Ji, Chunyi Hao, Lin Ye, Andrew J. Sanders, Wen G. Jiang	9
19	Fusobacterium nucleatum infection is correlated with tumor metastasis and postoperative survival of colorectal cancer patients in China 2016 ·Translational Cancer Research ·Yuan Sun, (unknown), Xiuyun Tian, (unknown), Xiaoya Guan, (unknown), Min Zhao, Chunyi Hao	8
20	CD44-Positive Cancer Stem Cells Expressing Cellular Prion Protein Contribute to Metastatic Capacity in Colorectal Cancer 2013 ·Cancer Research ·Lei Du, Guanhua Rao, Hongyi Wang, Baowei Li, Weili Tian, (unknown), Leya He, Brian Laffin, Xiuyun Tian, Chunyi Hao, (unknown), Xin Sun, Yushan Zhu, Dean G. Tang, Maryam Mehrpour, Youyong Lu, Quan Chen	88

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact